Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, thank you for standing by and welcome to Allogene Therapeutics First Quarter twenty twenty six Conference Call. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead. Thank you, operator, and welcome, everyone, to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the first quarter of twenty twenty six. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q and A session and will aim to keep the call to under an hour. I am joined today by Doctor. David Chang, President and Chief Executive Officer Doctor. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, potential treatment settings, and financial guidance, among other things. These forward looking statements are based on current information, assumptions, and expectations that are s...